### Amoxicillin + clavulanic acid

**Indication**: Multi-drug resistant Mycobacterium tuberculosis  
**ICD11 code**: ML32.00

**INN**: Amoxicillin + clavulanic acid

**Medicine type**: Chemical agent

**Antibiotic groups**: ACCESS

**List type**: Complementary

**Additional notes**: For use only in combination with meropenem or imipenem + cilastatin (EML). For use only in combination with meropenem (EMLc)

**Formulations**
- Oral > Liquid: 250 mg + 62.5 mg powder for oral liquid (EMLc)
- Oral > Solid: 500 mg (as trihydrate) + 125 mg (as potassium salt)

**EML status history**:  
- First added in 2019 (TRS 1021)  
- Changed in 2021

**Sex**: All

**Age**: Also recommended for children

**Therapeutic alternatives**: The recommendation is for this specific medicine

**Patent information**: Patents have expired in most jurisdictions  
Read more about patents.

**Wikipedia**: Amoxicillin + clavulanic acid

**DrugBank**: Amoxicillin, Clavulanic acid (Clavulanate)

---

**Expert Committee recommendation**

The Expert Committee recommended the deletion of amoxicillin + clavulanic acid oral liquid 125 mg + 31.25 mg /5 mL from the EMLc as requested in the application, noting that it is not an optimal, appropriate formulation for the treatment of tuberculosis, in line with recommendations in the current WHO tuberculosis treatment guidelines.